|[February 26, 2014]
Immunome Appoints New Management
WYNNEWOOD, Pa. --(Business Wire)--
Immunome, Inc., a biotechnology company with a unique and powerful
immunotherapy discovery engine for new cancer targets and therapeutics,
announces the appointment of three new members to its management team,
Jane H. Hollingsworth as executive chair; Joan Lau, PhD as chief
operating officer and Joel F. Sussman as chief financial officer.
Michael Widlitz, the company's lead director, said, "Jane, Joan and Joel
bring top tier industry, operational and scientific management
experience to the strong scientific team already in place. The addition
of this elite group demonstrates the commitment of the board and
investors to advancing its unique, paradigm-shifting cancer
immunotherapy technology. We are delighted to welcome them to the
management team. With their leadership and proven expertise, look
forward to a very bright future for the company."
Ms. Hollingsworth is a 20 year veteran of the pharmaceutical industry
and a proven leader in the field. She is founder and managing partner of
Militia Hill Ventures, a life sciences accelerator; founder and former
chief executive officer of NuPathe (PATH); founder and former executive
vice president of Auxilium Pharmaceuticals (AUXL) and former executive
vice president and general counsel of IBAH, a multinational clinical
research organization (IBAH). Ms. Hollingsworth srves on a number of
industry and civic boards and is a leader in building the life sciences
industry in the mid-Atlantic region.
Ms. Hollingsworth earned an undergraduate degree from Gettysburg College
and a JD from Villanova University.
Dr. Lau is founder and managing partner of Militia Hill Ventures and
former president and chief executive officer of two venture-backed
biotechnology companies, Azelon Pharmaceuticals and Locus
Pharmaceuticals. Previously, Dr. Lau held roles of increasing
responsibility in drug discovery and development and business
development at Merck & Co., Inc. Dr. Lau is also associate course
director for the Vagelos Program in Life Sciences Management at the
University of Pennsylvania and formerly served as executive-in-residence
at BioAdvance, a funder of life sciences companies in southeastern
Dr. Lau earned an undergraduate degree in bioengineering from the
University of Pennsylvania, an MBA from the Wharton School of the
University of Pennsylvania and a PhD in Neuroscience from the University
of Cincinnati College of Medicine.
Mr. Sussman is a financial management consultant who serves as chief
financial officer for early-stage life sciences companies. His present
and former clients include numerous venture-backed life sciences and
technology companies, including one that he joined to take the company
public and serve as its full-time chief financial officer until its sale
to a larger public company. Before beginning his consulting practice in
1995, he had fifteen years experience as chief financial officer and/or
treasurer of public and private technology and healthcare companies.
Mr. Sussman earned an undergraduate degree from Yale and an MBA from the
Wharton School of the University of Pennsylvania and is a licensed
certified public accountant.
Immunome is a biotechnology company with a unique and powerful
immunotherapy discovery engine for new cancer targets and therapeutics.
The proprietary technology and methods, originally discovered at MIT's (News - Alert)
Whitehead Institute, enable Immunome to simultaneously discover novel
cancer antigens and isolate native human antibodies that attack
cancer cells. The technology is a highly efficient immunotherapy
discovery engine, enabling the discovery of cancer antigens and
antibodies in only a few months, as opposed to the four or more years
with current discovery methods. No other platform provides such a rapid
and productive means for identifying and advancing the newest cancer
[ Back To TMCnet.com's Homepage ]